Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. Molecular Medicine / 分子醫學研究所
  4. Serum Mesothelin in Epithelial Ovarian Cancer: a New Screening Marker and Prognostic Factor
 
  • Details

Serum Mesothelin in Epithelial Ovarian Cancer: a New Screening Marker and Prognostic Factor

Date Issued
2006
Date
2006
Author(s)
Tzeng, Yu-Lin
DOI
zh-TW
URI
http://ntur.lib.ntu.edu.tw//handle/246246/51387
Abstract
Objective. To investigate the relationship between serum mesothelin and clinico-pathological factors, and to determine whether mesothelin is a biomarker for detection and an independent prognostic factor of ovarian cancer. Methods. Twenty-four normal populations, 20 women with benign ovarian lesion, or 122 patients with epithelial ovarian cancer were enrolled. Clinical and pathologic items were recorded. Pretreatment mesothelin and CA125 serum samples of these women were measured by an enzyme-linked immunosorbent assay. The results were correlated to clinical data. The histopathologic items and serum meosthelin, and CA125 influencing clinical outcome were evaluated comparatively. Results. The preoperative serum levels of mesothelin (OD450 ratio) (2.465 vs. 1.384 vs. 0.912) were higher in ovarian cancer patients than in those with benign ovarian lesions or normal populations. The preoperative serum levels of mesothelin also significantly increased from stage I to IV. Elevated mesothelin serum levels before therapy (1.51 (1.02-2.24), Relative risk (95%CI)) and advanced stages (1.61 (1.03-2.49)) showed significantly poorer overall survival (OS) for 122 cancer patients. Elevated mesothelin serum levels before therapy also revealed significantly poorer OS for 83 cancer patients with optimal debulking surgery (1.59 (1.02-2.48)) and for 79 advanced-staged cancer patients (2.18 (1.09-4.38)). Conclusions. Pretreatment mesothelin serum levels might be regarded a new tumor marker for the differential diagnosis of ovarian cancer and an additional prognostic factor in predicting the outcome of ovarian carcinoma patients.
Subjects
卵巢癌
篩選標記
ovarian cancer
screening marker
SDGs

[SDGs]SDG3

Type
other
File(s)
Loading...
Thumbnail Image
Name

ntu-95-P93448012-1.pdf

Size

23.31 KB

Format

Adobe PDF

Checksum

(MD5):2655f57b8acec5332a6a520b9b1b5db6

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science